Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
HOME > LATEST
LATEST
-
BUSINESS MSD Files for Keytruda Label Expansion in Ovarian Cancer
October 31, 2025
-
BUSINESS Astellas Beats H1 Forecast on Strategic Product Growth, Cost Controls
October 31, 2025
-
BUSINESS Vyvanse Generics Drag Takeda Earnings; FY2025 Outlook Trimmed
October 31, 2025
-
BUSINESS Pfizer Resumes Supply of Smoking Cessation Pill Champix after 4 Years
October 31, 2025
-
BUSINESS Ono’s Sales Rise 7% on Overseas Growth of Qinlock, Romvimza
October 31, 2025
-
REGULATORY LDP Eyes Support for Drug Wholesalers in Upcoming Economic Package
October 31, 2025
-
REGULATORY Shionogi/Sage’s Zurzuvae Clears MHLW Panel, Label Wording on Combo Use under Review
October 31, 2025
-
BUSINESS Leqembi’s April-September Sales at 41.1 Billion Yen: Eisai
October 31, 2025
-
BUSINESS TMS Founder Sees “Ray of Hope” in Novel Stroke Drug TMS-007
October 31, 2025
-
COLUMN The Unseen Edge & the Shadow of Bias: Awareness as the Cornerstone of Leadership Success
October 31, 2025
-
BUSINESS Jardiance Dominates September Detailing Rankings with Five Wins: Intage
October 31, 2025
-
REGULATORY Japan Mulls Full Overhaul of LLP Rule under FY2026 Drug Pricing Reform
October 30, 2025
-
REGULATORY Data Error Delayed Japan Review of Subcutaneous Rybrevant; Approval Still Expected This Year
October 30, 2025
-
BUSINESS MSD Launches 21-Valent Pneumococcal Vaccine Capvaxive in Japan
October 30, 2025
-
BUSINESS AbbVie Files Skyrizi for Pediatric Dosage in Japan
October 30, 2025
-
REGULATORY Japan to Delist 506 Drugs from NHI Price List, Including Category A Products and LLPs
October 30, 2025
-
REGULATORY Exclude High-Price-Gap Products from Unprofitable Drug Re-Pricing: Chuikyo
October 30, 2025
-
REGULATORY FIRM Urges Continued Premiums for Conditionally Approved Regenerative Medicines
October 30, 2025
-
REGULATORY Japan Eyes Review of Generic Price Bands, Brand-Based Revisions for Tier A Products
October 30, 2025
-
BUSINESS LifeScan Japan Taps AI to Fast-Track Sales Force Development, Draws Interest from Pharma
October 29, 2025
ページ
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…